Latest Headlines

Latest Headlines

Illumina cites ambitious growth plans amid Q2 miss and stock tumble

It has been a busy year for Illumina, with deals to expand its product offerings and increase its footprint in growing markets. And the company is counting on new technology to keep up the positive momentum, especially in light of second quarter revenues that missed for the first time in years and stock crashing upon the news.  

Illumina wraps lab automation and software around HiSeq X to lower barrier to mass sequencing

Illumina has introduced a suite of tools and software to help research organizations new to population-scale sequencing to get started with its HiSeq X Ten and Five systems. The move comes one month after BGI joined the large-scale sequencing field with a package that covers each step of the process, from sample preparation to data analysis.

Illumina launches new lab service for HiSeq X sequencing systems

Illumina is riding high off its HiSeq X sequencing systems, meeting increased demand with expanded facilities and ambitious plans for growth. Now, the company is rolling out a service to help labs use its HiSeq X products, allowing facilities to harness Illumina's sequencing expertise to better operate the systems.

Illumina unveils plans for new European HQ and science center

Illumina is laying out plans for expansion, signing a 20-year lease on a 155,000-square-foot facility in Cambridge, England.

Genomics giant Illumina blueprints new Euro HQ/science center in Cambridge, UK

The gene-sequencing pioneers at Illumina are planning to build a major new science center and European headquarters in the U.K.'s growing biotech hub in Cambridge. Illumina signed a lease on a 155,000-square-foot facility, designed to grow another 70,000 square feet as needed for future expansion.

Merck KGaA partner Genea gets CE mark for a pair of IVF technologies

Genea Biomedx partnered its three fertility products in development with Merck KGaA last month. Now it's won a CE mark for two of them: the Gavi automated vitrification instrument and the Geri benchtop incubator.

Twist on IT hiring spree as Illumina backs $37M fundraising round

Twist Bioscience is set to grow its headcount by 50% after it raised $37 million from Illumina and other investors to move its DNA synthesis technology toward commercialization. And IT hires feature heavily in the startup's plans, with half of the current job openings relating to bioinformatics, Python databases and other niches in the field.

Illumina teams up with Chinese genomics firm for noninvasive prenatal test development

Illumina and Chinese genomics company Annoroad are joining forces to develop noninvasive prenatal screening tools based on next-generation sequencing technology, a potentially fruitful collaboration as Illumina looks to gain ground in emerging markets and strengthen its foothold in a saturated prenatal testing field.

Illumina helps add a $37M Twist on DNA synthesis

San Francisco-based Twist Bioscience has added a $37 million C round to ramp up commercialization efforts for a new tech platform that synthesizes DNA on silicon, promising to spark an industrial-scale shift that will dwarf the traditional approach to R&D that has long been in use.

Illumina slaps Roche's Ariosa with a prenatal testing IP suit

San Diego's Illumina announced that it is filing a patent infringement suit against Roche's Ariosa Diagnostics and its microarray-based Harmony Prenatal Test. The gene sequencing company accuses Ariosa of violating its '794 patent, called "Multiplex Nucleic Acid Reactions."